Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands		3 Months Ended
		Sep. 30, 2023	Sep. 30, 2022
Net revenue:
Total net revenue		$ 103,892	$ 96,493
Cost of revenue:
Total cost of revenue	[1]	64,399	61,896
Gross profit		39,493	34,597
Operating expenses:
Research and development	[2]	14,013	14,092
Selling and marketing		10,244	10,795
General and administrative		13,023	11,892
Total operating expenses		37,280	36,779
Income (loss) from operations		2,213	(2,182)
Income (loss) from equity method investment, net		431	(368)
Other expense, net		(3,681)	(2,558)
Loss before provision for income taxes		(1,037)	(5,108)
Provision for income taxes		1,932	341
Net loss		$ (2,969)	$ (5,449)
Net loss per share - basic		$ (0.03)	$ (0.06)
Net loss per share - diluted		$ (0.03)	$ (0.06)
Weighted average common shares used in computing net loss per share:
Basic		96,555	93,529
Diluted		96,555	93,529
Net Income (Loss)		$ (2,969)	$ (5,449)
Foreign currency translation adjustment		(2,138)	(3,655)
Comprehensive loss		(5,107)	(9,104)
Products
Net revenue:
Total net revenue	[3]	53,350	44,623
Cost of revenue:
Total cost of revenue		35,699	28,850
Services
Net revenue:
Total net revenue	[4]	50,542	51,870
Cost of revenue:
Total cost of revenue		$ 28,700	$ 33,046

[1] Includes cost of revenue from sales to the joint venture, an equity method investment, of $15,271 and $5,907 during the three months ended September 30, 2023 and 2022, respectively.

[2] Includes charge backs to the joint venture, an equity method investment, related to research and development of $132 and $779 during the three months ended September 30, 2023 and 2022, respectively.

[3] Includes sales of products to the joint venture, an equity method investment, of $21,952 and $8,869 during the three months ended September 30, 2023 and 2022, respectively. See Note 13.

[4] Includes sales of services to the joint venture, an equity method investment, of $2,854 and $2,957 during the three months ended September 30, 2023 and 2022, respectively, See Note 13.